Hepatitis C virus (HCV) infection is a serious disease, which chronically infects 71 million people worldwide. Currently oral interferon (IFN)-free regimen usage involving a combination of direct-acting antiviral agents (DAAs) is capable of providing a sustained virologic response (SVR) of >90%. However, a number of DAA-resistant HCV strains have emerged and many patients do not have access to this therapy owing to its high cost. Combination drug therapy is one strategy for lowering cost and improving effectiveness of antiviral therapy. Chalepin from Ruta angustifolia is known to exhibit strong anti-hepatitis C activity. Anti-HCV efficacies of combinations of chalepin and current antiviral drugs, namely, cyclosporine A (CsA), daclatasvir (DCV). IFN-α, ribavirin (RBV), simeprevir (SMV), and telaprevir (TVR) were measured by treating HCV-infected cells in vitro. Chalepin enhanced anti-HCV activities of CsA, DCV, IFN-α, RBV, SMV, and TVR with a synergistic combination index of <1. The results suggest drug combinations that include chalepin should be considered when developing alternative and complementary medicine as anti-HCV agents.
|Number of pages||8|
|Journal||Southeast Asian Journal of Tropical Medicine and Public Health|
|Publication status||Published - Jan 2020|
- Combination drug treatment
- Direct-acting antiviral
- Hepatitis C virus
- Ruta angustifolia